Dechert Advises Femasys in IPO
June 23, 2021
Dechert has advised Femasys Inc., a biomedical company focused on transforming women's healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas, on its initial public offering of 2,650,000 shares of its common stock at a public price of $13.00 per share. The transaction was announced on June 17.
The Dechert team includes corporate partner David Rosenthal, and associates Anna Tomczyk and Christopher Polisano; employee benefits associate Jake Phillips; and tax partner Joshua Milgrim.
About Dechert
Dechert is a leading global law firm with 24 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
Related Professionals
